BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 7826071)

  • 1. [Successful treatment of refractory anemia with excess of blasts in transformation with cytarabine ocfosfate].
    Takeuchi M; Kojima K; Takaba S; Isokawa M; Tanimizu M; Kimura F; Ohmoto E; Harada M
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):141-4. PubMed ID: 7826071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Complete remission by cytarabine ocfosfate plus G-CSF therapy in a patient with hypoplastic RAEB-T].
    Kadowaki I; Sasaki O; Sasaki T; Ishizawa K; Kimura J; Nomura J; Furuyama K; Harigae H; Shishido T; Okuda M
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):145-7. PubMed ID: 7529978
    [No Abstract]   [Full Text] [Related]  

  • 3. [A combination chemotherapy with cytarabine ocfosfate, low dose etoposide, and G-CSF for the treatment of high risk MDS (RAEB, RAEBt)--a pilot study].
    Hara M; Kojima K; Azuma T; Narumi H; Shinagawa K
    Rinsho Ketsueki; 1998 Apr; 39(4):314-6. PubMed ID: 9597900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Successful treatment of acute myelogenous leukemia in an elderly patient with cytarabine ocfosfate].
    Inaba T; Shimazaki C; Tatsumi T; Yamagata N; Hirata T; Goto H; Fujita N; Nakagawa M; Fujita N; Miyazaki S
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):535-8. PubMed ID: 8129396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypoplastic leukemia successfully treated by oral administration with cytarabine ocfosfate].
    Okuyama Y; Kitazume K; Iwabe K; Usuki K; Urabe A
    Rinsho Ketsueki; 1994 Jun; 35(6):593-7. PubMed ID: 8078195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Refractory anemia with excess myeloblast in transformation induced remission by combined oral administration of cytarabine ocfosfate and 6-mercaptopurine].
    Fukumi S; Mizorogi F; Matsuo A; Sato H; Abe T
    Gan To Kagaku Ryoho; 1995 Jun; 22(7):945-8. PubMed ID: 7794001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Successful treatment of acute myelomonocytic leukemia developed from MDS with cytarabine ocfosfate (SPAC)].
    Wake A; Takazawa A; Serino Y; Tonai S; Nakanishi M; Murakami S; Ogawa R; Nagata K; Mori N; Nakata K
    Gan To Kagaku Ryoho; 1995 Feb; 22(3):395-8. PubMed ID: 7880111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Low-dose cytarabine ocfosfate therapy in an elderly acute myelogenous leukemia].
    Hamaoka R; Jozaki K; Amano T; Itoh H; Imai Y; Nishikawa M; Kurokawa M; Yonezawa T; Chinen Y
    Gan To Kagaku Ryoho; 1995 May; 22(6):819-22. PubMed ID: 7755392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies].
    Ueda Y; Mori S; Ito T; Maesako Y; Konishi H; Yagiri Y
    Rinsho Ketsueki; 1998 May; 39(5):348-54. PubMed ID: 9637884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
    Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
    Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of refractory hematologic malignancies by combination of cytarabine ocfosfate and etoposide].
    Kiyama Y; Suzuki G; Masauzi N; Ohizumi H; Kobayashi N; Ogasawara M; Naohara T; Saito M; Higa T; Kasai M
    Gan To Kagaku Ryoho; 1996 Oct; 23(12):1717-20. PubMed ID: 8886052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
    Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
    Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A new antileukemic drug, cytarabine ocfosfate].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1993 Sep; 20(12):1877-83. PubMed ID: 8379682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of RAEB-t treated by G-CSF showing complete remission after MST-16 treatment for subsequent reversible leukemia].
    Murate T; Ohashi H; Kagami Y; Hotta T; Murase T; Hirota Y; Kimura K
    Gan To Kagaku Ryoho; 1991 Sep; 18(12):2155-8. PubMed ID: 1716093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral administration of cytarabine ocfosfate and ondansetron hydrochloride in patients with acute myeloid leukemia who can not be treated with intensive chemotherapy:--attempt to make their quality of life better].
    Yano K; Matsui H; Fujisawa S
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):427-30. PubMed ID: 9492840
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of acute myeloid leukemia and myelodysplastic syndrome with orally administered cytarabine ocfosfate and granulocyte colony-stimulating factor.
    Okumura H; Yoshida T; Takamatsu H; Katoh T; Murashima M; Watanabe A; Yamauchi H; Matano S; Chuhjo T; Takeshima M; Kaya H; Ohtake S; Nakamura S; Matsuda T
    Int J Hematol; 1997 Apr; 65(3):263-8. PubMed ID: 9114597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Five cases of myelodysplastic syndrome treated with cytarabine ocfosfate].
    Nishi T; Funasako M; Hata N; Andoh K; Itoh Y; Ono H; Itoh K; Sato Y; Sato H; Taniji M; Nakai S; Ueda A; Fujimoto H; Ohata M
    Gan To Kagaku Ryoho; 1996 Sep; 23(10):1331-4. PubMed ID: 8831748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phase II study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate) on hematological malignancies].
    Tatsumi N; Yamada K; Ohshima T; Nakamura T; Ohno R; Masaoka T; Kimura I; Kimura K
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2387-95. PubMed ID: 2260876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mast cell leukemia evolved from RAEB-T (5q-syndrome) in a 12 year-old girl].
    Sugita K; Kaneko T; Sekine Y; Taguchi N; Miyauchi J
    Rinsho Ketsueki; 1996 May; 37(5):430-6. PubMed ID: 8691590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.